IP Library › Assignment 061493/0885

Patent Assignment

Reel/Frame 061493/0885

Change of Owner/Applicant's Address

Recorded: 2022-09-21 Pages: 4

View PDF Order Certified Copy

Assignor

LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

Executed: 2022-02-02

Assignee

LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

TOUR W, 102 TERRACE BOIELDIEU 19EME ETAGE, PUTEAUX, 92800, FRANCE

Covered Properties (57)

Anti-Fibrinogen Aptamers

Patent: 12,281,312 →

Application: 17/389,878 →

Publication: US 2022/0098590

Factor VII Composition Having a Substantially Homogeneous Isoelectric Point

Application: 16/868,850 →

Publication: US 2020/0362329

Oral Composition of Anti-Tnf Alpha Antibodies

Application: 16/697,519 →

Publication: US 2020/0331994

Fc Mutants with Modified Functional Activity

Patent: 11,649,271 →

Application: 15/554,022 →

Publication: US 2018/0030111

Method for the Cryopreservation of Cells for Therapeutic Purposes

Patent: 11,412,730 →

Application: 15/737,469 →

Publication: US 2019/0000070

Use of Modified Fc Fragments in Immunotherapy

Patent: 12,247,076 →

Application: 15/742,268 →

Publication: US 2018/0355034

Fc Mutants with Improved Functional Activity

Patent: 11,814,438 →

Application: 16/315,356 →

Publication: US 2019/0309085

Stable Liquid Fibrinogen

Application: 16/315,388 →

Publication: US 2019/0209659

Fc Polypeptide Variants Having an Increased Half-Life

Application: 16/345,620 →

Publication: US 2019/0292269

Method for the Cryopreservation of Cells for Therapeutic Purposes

Patent: 11,785,937 →

Application: 16/766,900 →

Publication: US 2021/0244016

Variants with Fc Fragment Having an Increased Affinity for Fcrn and an Increased Affinity for at Least One Receptor of the Fc Fragment

Application: 16/772,244 →

Publication: US 2021/0214434

Composition of Concentrated Human Immunoglobulins

Application: 17/056,626 →

Publication: US 2021/0205452

Combination of Factor Vii and an Anti-Factor Ix/X Bispecific Antibody

Application: 17/251,695 →

Publication: US 2022/0152197

Method of Preserving Cells for Therapeutic Use

Application: 17/293,867 →

Publication: US 2022/0226383

Sampling Device for Sampling from a Surface of an Industrial Vessel Without Requiring a Person to Descend into an Industrial Vessel, Using a Swab

Patent: 12,025,539 →

Application: 17/297,504 →

Publication: US 2022/0034758

Method for Filtering Fibrinogen

Patent: 12,570,721 →

Application: 17/416,143 →

Publication: US 2022/0056107

Glycols as Pathogen Inactivating Agents

Application: 16/162,735 →

Publication: US 2019/0254276

Glycols as Pathogen Inactivating Agents

Patent: 11,553,712 →

Application: 13/994,207 →

Publication: US 2013/0324619

Cetuximab with Modified Glycosylation and Uses Thereof

Application: 14/767,089 →

Publication: US 2016/0002330

Optimized Fc Variants

Patent: 8,742,074 →

Application: 13/257,502 →

Publication: US 2012/0009188

Optimized Fc Variants

Patent: 45,992 →

Application: 14/338,413 →

Optimized Fc Variants

Patent: 46,585 →

Application: 14/993,277 →

Method for Purifying Transgenic Factor Vii/Viia

Patent: 9,982,247 →

Application: 14/415,254 →

Publication: US 2015/0175983

Use of Mutagenic Dna Polymerase for Producing Random Mutations

Patent: 7,670,809 →

Application: 10/416,424 →

Publication: US 2004/0110294

Method for Stabilising an Immunoglobulin G Composition in Liquid Form

Patent: 9,463,241 →

Application: 13/752,189 →

Publication: US 2013/0202585

Stabilising Formulation for Immunoglobulin G Compositions in Liquid Form and in Lyophilised Form

Patent: 8,388,954 →

Application: 10/552,314 →

Publication: US 2007/0036779

Method for Stabilizing a Cryoprecipitate of Plasmatic Proteins for Being Subjected to a Viral Inactivation Thermal Treatment

Patent: 7,727,743 →

Application: 10/563,620 →

Publication: US 2006/0247426

Use of ADCC-Optimized antibodies for treating weak patients

Patent: 8,501,171 →

Application: 12/659,824 →

Publication: US 2010/0303826

Use of Adcc-Optimized Antibodies for Treating Weak Patients

Patent: 9,109,020 →

Application: 13/930,070 →

Publication: US 2014/0017243

Use of Adcc-Optimized Antibodies for Treating Low-Responder Patients

Patent: 9,879,089 →

Application: 14/702,143 →

Publication: US 2015/0307624

Use of Adcc-Optimized Antibodies for Treating Low-Responder Patients

Patent: 7,713,524 →

Application: 10/566,358 →

Publication: US 2006/0182741

Virally-Safe Factor Viii with a Low Content of Higher Multimers

Patent: 7,932,355 →

Application: 10/576,794 →

Publication: US 2007/0275880

Albumin-Purification Method Comprising a Nanofiltration Step, Solution, and Composition for Therapeutic Use Containing the Same

Patent: 9,611,311 →

Application: 14/611,460 →

Publication: US 2015/0152162

Albumin-Purification Method Comprising a Nanofiltration Step, Solution, and Composition for Therapeutic Use Containing the Same

Patent: 10,562,957 →

Application: 15/443,884 →

Publication: US 2017/0166626

An Antibody Method for Treatment of a Disease in Which the Target Cells Are Cells Which Express CD20

Patent: 9,873,745 →

Application: 14/828,177 →

Publication: US 2016/0060350

A Monoclonal Antibody Directed Against CD20 Antigen

Patent: 9,234,045 →

Application: 11/793,138 →

Publication: US 2009/0053233

Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins

Patent: 8,598,319 →

Application: 11/477,212 →

Publication: US 2008/0207878

Process for Separating Proteins Fibrinogen, Factor Xiii and Biological Glue from a Solubilized Plasma Fraction and for Preparing Lyophilised Concentrates of Said Proteins

Patent: 9,339,530 →

Application: 14/056,886 →

Publication: US 2014/0148580

Process for Separating Proteins Fibrinogen, Factor Xiii and Biological Glue from a Solubilized Plasma Fraction and for Preparing Lyophilised Concentrates of Said Proteins

Patent: 9,320,779 →

Application: 14/056,903 →

Publication: US 2014/0154231

The Invention Relates to a Method of Viral Inactivation by Dry Heating

Patent: 8,252,227 →

Application: 12/097,860 →

Publication: US 2009/0297398

Immunoglobulin G (Igg) Concentrate Depleted of Anti-a and Anti-B Antibodies and of Polyreactive Iggs

Patent: 8,153,382 →

Application: 12/159,199 →

Publication: US 2009/0074749

Recombinant or Transgenic Factor Vii Composition, Each Factor Vii Molecule Having Two N-Glycosylation Sites with Defined Glycan Units